Chemical Namesatralizumab-mwge
Dosage FormInjection (subcutaneous; 120 mg/mL)
Drug ClassMonoclonal antibodies
CompanyGenentech Inc.
Approval Year2020


  • To treat neuromyelitis optica spectrum disorder (NMOSD) in adults who are AQP4-IgG(+).
Last updated on 12/9/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Enspryng (satralizumab-mwge) Precsribing Information 2020Genentech Inc., South San Francisco, CA